Skip to search formSkip to main contentSkip to account menu

Malignant neoplasm of stomach stage IV

Known as: gastric cancer, metastatic, metastatic stomach cancer, Stage IV Gastric Cancer AJCC v7 
Stage IV includes: (Any T, Any N, M1). M1: Distant metastasis. (AJCC 7th ed.)
National Institutes of Health

Related topics

Related topics

12 relations
Epithelial CellsEpitheliumGastric carcinoma stage IVGastric mucosa

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer
Background Gene expression profiling has contributed greatly to cancer research. However, expression-driven biomarker discovery… 
2015
2015
Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen
Chemotherapy-induced neutropenia (CIN) reportedly indicated better prognosis for some cancers. We retrospectively analyzed 150… 
2012
2012
The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.
BACKGROUND The prognostic role of matrix metalloproteinase-9 (MMP-9) in metastatic gastric cancer has not been validated… 
2011
2011
Trastuzumab in HER2-Positive Metastatic Gastric Cancer
Withmore than 900 000 new cases annually, gastric cancer is the fourth most prevalent cancer worldwide and, with 700 000 deaths… 
Review
2009
Review
2009
Standard First-Line Chemotherapy for Metastatic Gastric Cancer in Japan Has Met the Global Standard: Evidence From Recent Phase III Trials.
In Japan, standard first-line chemotherapy for metastatic gastric cancer was initially 5-fluorouracil (5-FU) monotherapy. This is… 
Review
2008
Review
2008
Changes of histology and expression of MMP-2 and nm23-H1 in primary and metastatic gastric cancer.
AIM To investigate the changes of histology and expression of MMP-2 and nm23-H1 in primary and metastatic gastric cancer… 
Review
2005
Review
2005
Phase II Study of Low-Dose Docetaxel/Fluorouracil/Cisplatin in Metastatic Gastric Carcinoma
Objectives:In several recent reports, docetaxel (75–85 mg/m2) combined with fluorouracil (5-FU) and cisplatin has shown… 
Highly Cited
2002
Highly Cited
2002
De Gramont Schedule is a Very Low Toxic and Effective Regimen in Low Performance Status Patients Affected by Metastatic Gastric Cancer: Preliminary Report
Summary Treatment of patients affected by metastatic gastric cancer with low performance status (PS) is a very hard choice. It is… 
1996
1996
A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer.
1993
1993
Subcutaneous Therapy with Low-Dose Interleukin-2 plus the Neurohormone Melatonin in Metastatic Gastric Cancer Patients with Low Performance Status
Aims and background Patients with disseminated gastric cancer are generally in very bad clinical conditions, which make them not… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)